Clin2
NCT04422366Possibly a fitRecruiting

9-valent HPV vaccine study for healthy Chinese women

Cervical CancerVulvar CancerVaginal CancerCIN1CIN2CIN3VaIN1VaIN2

Part of Cancer, Infections, Skin, Women’s health & pregnancy clinical trials.

This trial tests a 9-type HPV vaccine to see how well it works, how it helps the body build protection, and whether it’s safe. It’s for healthy Chinese women who have not had HPV vaccination before and meet specific health and timing requirements.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
8,000 people
Ages
20 years to 45 years
Study type
Interventional

Who can take part

  • Be a Chinese woman age 20 to 45 and have valid legal identification
  • You can understand the study and sign informed consent, including follow-up visits
  • Your recent sexual/activity and gynecology visit timing must match the rules (including no sex 48 hours before sample-collection visits, and no vaginal cleansing/medications 72 hours before)
  • You must not have received any HPV vaccine before or during the study, including past trials
  • Your pregnancy test must be negative at enrollment and you must use effective birth control during the required time window
  • You must not have certain past HPV/major genital conditions, immune problems, or recent vaccines/illnesses that could affect safety

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06756269Recruiting· Phase 2
HPV vaccine study for people aged 9 to 45

This trial tests a new 15-valent HPV vaccine to see if it is safe and creates a strong immune response. If you are between 9 and 45 years old and have not had an HPV vaccine before, you may be able to join.

Nanning, Guangxi
NCT05027776Recruiting· Phase 3
HPV vaccine study for healthy girls and young women

This trial studies whether a quadrivalent HPV vaccine is safe and helps the body build protection (immunity) against HPV. It enrolls healthy Chinese females who are not already treated for HPV-related infection.

Mianyang, Sichuan
NCT06681636Not yet recruiting· Phase 2
HPV vaccine immune study in Vietnamese women

This trial tests how well the HPV vaccine triggers immune memory in women who may have been exposed to HPV. It could help protect against future HPV infections and related cancers.

Parkville, Victoria
NCT04910802Recruiting· Phase 4
HPV vaccine with routine HPV screening for ages 22–26

This study looks at giving the HPV vaccine (Gardasil 9) to women while they go through Sweden’s routine HPV screening. It helps researchers understand how vaccine use alongside screening affects HPV infection and cervical cancer prevention.

Stockholm
NCT05371353Recruiting
Study of how long HPV vaccine immunity lasts

This study checks how well the HPV (cancer-preventing) vaccine protection stays in your body over time. It may help confirm the vaccine’s “long-lasting” immune response and guide future vaccination confidence.

Yangchun, Guangdong
NCT05262010Recruiting· Phase 3
HPV vaccine study for Chinese women, ages 9–45

This trial tests an 11-type HPV vaccine to prevent infection from multiple HPV strains. If you enroll, you’ll receive scheduled vaccine doses and have health and gynecologic check-ins to see how well the vaccine works and is tolerated.

Hechi, Guangxi

Hear when a new Cervical Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.